Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Tidal Investments LLC

Tidal Investments LLC lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 57.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,353 shares of the pharmaceutical company's stock after acquiring an additional 6,672 shares during the period. Tidal Investments LLC's holdings in Vertex Pharmaceuticals were worth $7,391,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in VRTX. Truvestments Capital LLC increased its position in shares of Vertex Pharmaceuticals by 30.3% during the 4th quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock valued at $40,000 after purchasing an additional 23 shares during the last quarter. Simon Quick Advisors LLC increased its position in Vertex Pharmaceuticals by 1.1% during the fourth quarter. Simon Quick Advisors LLC now owns 2,236 shares of the pharmaceutical company's stock valued at $900,000 after acquiring an additional 24 shares during the last quarter. Spinnaker Trust raised its stake in shares of Vertex Pharmaceuticals by 2.1% in the fourth quarter. Spinnaker Trust now owns 1,235 shares of the pharmaceutical company's stock valued at $497,000 after acquiring an additional 25 shares during the period. Strategic Advisors LLC lifted its holdings in shares of Vertex Pharmaceuticals by 0.6% in the 4th quarter. Strategic Advisors LLC now owns 4,486 shares of the pharmaceutical company's stock worth $1,807,000 after acquiring an additional 25 shares during the last quarter. Finally, Moors & Cabot Inc. boosted its stake in shares of Vertex Pharmaceuticals by 0.7% during the 4th quarter. Moors & Cabot Inc. now owns 3,603 shares of the pharmaceutical company's stock worth $1,451,000 after purchasing an additional 25 shares during the period. Hedge funds and other institutional investors own 90.96% of the company's stock.

Wall Street Analysts Forecast Growth

VRTX has been the subject of a number of recent analyst reports. The Goldman Sachs Group reissued a "buy" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Wall Street Zen upgraded Vertex Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Tuesday, March 11th. William Blair restated an "outperform" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Piper Sandler dropped their target price on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an "overweight" rating on the stock in a report on Monday, January 27th. Finally, Morgan Stanley lifted their price target on Vertex Pharmaceuticals from $462.00 to $464.00 and gave the company an "equal weight" rating in a report on Tuesday, May 6th. Thirteen research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $515.04.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 530 shares of Vertex Pharmaceuticals stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $475.34, for a total transaction of $251,930.20. Following the completion of the transaction, the executive vice president now owns 58,539 shares in the company, valued at approximately $27,825,928.26. This trade represents a 0.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP David Altshuler sold 3,231 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the transaction, the executive vice president now directly owns 26,512 shares of the company's stock, valued at approximately $13,256,000. This trade represents a 10.86% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,813 shares of company stock valued at $1,889,514 over the last 90 days. Insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock traded up $1.97 during trading hours on Friday, hitting $436.00. 1,427,218 shares of the stock traded hands, compared to its average volume of 1,416,571. The firm's 50 day moving average price is $476.26 and its 200-day moving average price is $462.91. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The stock has a market capitalization of $111.96 billion, a price-to-earnings ratio of -198.18, a P/E/G ratio of 2.11 and a beta of 0.51. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The firm had revenue of $2.77 billion during the quarter, compared to analysts' expectations of $2.85 billion. During the same quarter in the prior year, the company earned $4.76 EPS. Vertex Pharmaceuticals's quarterly revenue was up 2.6% on a year-over-year basis. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.